S
44.78
-0.16 (-0.36%)
| Previous Close | 44.94 |
| Open | 44.59 |
| Volume | 446,297 |
| Avg. Volume (3M) | 511,861 |
| Market Cap | 2,053,489,792 |
| Price / Book | 13.47 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -4.38 |
| Total Debt/Equity (MRQ) | 21.55% |
| Current Ratio (MRQ) | 15.68 |
| Operating Cash Flow (TTM) | -69.10 M |
| Levered Free Cash Flow (TTM) | -7.47 M |
| Return on Assets (TTM) | -45.06% |
| Return on Equity (TTM) | -87.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Soleno Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.93% |
| % Held by Institutions | 113.72% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 123.00 (Cantor Fitzgerald, 174.68%) | Buy |
| Median | 103.50 (131.13%) | |
| Low | 81.00 (Guggenheim, 80.88%) | Buy |
| Average | 103.17 (130.39%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 69.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Mar 2025 | 100.00 (123.31%) | Buy | 71.99 |
| 03 Mar 2025 | 70.00 (56.32%) | Buy | 45.80 | |
| Guggenheim | 28 Mar 2025 | 81.00 (80.88%) | Buy | 71.99 |
| Stifel | 28 Mar 2025 | 108.00 (141.18%) | Buy | 71.99 |
| 05 Mar 2025 | 74.00 (65.25%) | Buy | 44.99 | |
| Baird | 27 Mar 2025 | 102.00 (127.78%) | Buy | 67.39 |
| Cantor Fitzgerald | 27 Mar 2025 | 123.00 (174.68%) | Buy | 67.39 |
| Laidlaw & Co. | 27 Mar 2025 | 105.00 (134.48%) | Buy | 67.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Mar 2025 | Announcement | Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome |
| 27 Feb 2025 | Announcement | Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results |
| 29 Jan 2025 | Announcement | Soleno Therapeutics to Participate in Upcoming February Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |